Stock jumps on data: Shares rose 14% after Phase 1 results showed strong immune responses and no serious safety issues for Moderna’s hantavirus vaccine. Platform potential: Analysts see the results as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results